Mazor Robotics Guidance System Successfully Completes its 10,000th Procedure

Mazor Robotics Ltd. (TASE:MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced today that the 10,000th spinal surgery in which Mazor Robotics’ guidance system (Renaissance as well as the earlier Spine Assist) was used has been completed successfully. The Renaissance Guidance System was launched in mid 2012 and is being used by orthopedic and neurosurgeons to perform a wide range of spine and brain surgeries.

“As we approach 50 Renaissance Guidance Systems in the US, our goal is to accelerate the adoption of the system, to make it the standard of care for spinal surgeons across the country,” said Ori Hadomi, CEO of Mazor Robotics. “While we are very proud of the tools we have built for the surgeons using Renaissance, what is most rewarding for the team at Mazor is to see the way our system enables patients to quickly get back on their feet and resume their daily activities, a reality that many would have thought impossible only a few years ago.”

Renaissance improves the execution and results in a wide variety of spine procedures, including minimally-invasive and percutaneous degenerative repair, vertebrae stabilization and fixation for complex spinal deformity as well as vertebral augmentation. To date, Renaissance has been used in over 1,000 complex spinal deformity correction procedures and thousands of minimally invasive procedures. Additionally, Renaissance has been used in a variety of brain operations, including Deep Brain Stimulation procedures.

There is a growing body of clinical data on the Renaissance Guidance System with over 50 publications in major professional journals and podium presentations at major international meetings, demonstrating the superior performance over standard techniques. Demonstrating the flexibility of the system, the youngest patient to be operated on using Renaissance was five years old and the oldest patient was 92 years old.

By affording orthopedic and neurosurgeons the ability to create a pre-operative blueprint of the ideal surgery for each patient in a virtual 3D environment as well as providing them with a sophisticated guidance system, Renaissance gives surgeons the peace of mind that they can perform simple as well as complex procedures with predictable results and potentially through a much less invasive approach.

“I have been incorporating Mazor Robotics technology into my practice for over five years now,” said pediatric orthopedic surgeon Dr. Dennis Devito of Children’s Orthopedics of Atlanta (COA), GA. “I find it provides improved patient care through enhancement of the surgeon’s capabilities. As a surgeon that has many patients with severe spinal deformity, the Renaissance Guidance System allows me to visualize and plan my surgery so I can focus my attention on correcting my patients’ curve.”

Mazor anticipates its Renaissance Guidance System will be used in over three thousand spine and brain procedures in 2015. As surgeons and hospital administrators become more broadly aware of its benefits, the Company expects this to significantly grow over the coming years as the number of systems and surgeons using Renaissance increases.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

U.S. Contacts: EVC Group

Michael Polyviou/Doug Sherk – Investors

212.850.6020; 646-445-4800

David Schemelia – Media


Latest Tweet

Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf…
Follow Mazor Robotics on Twitter
©2018 Mazor Robotics. All Rights Reserved. Designed By Medtech Momentum